R-FCM Regimen - CISMeF

Preferred Label : R-FCM Regimen;

NCIt synonyms : Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone Regimen; FCMR Regimen;

NCIt related terms : R-FCM; R-FCM (rituximab-blit); R-FCM (rituximab-abbs); R-FCM (rituximab-rite); R-FCM (rituximab-rixi); R-FCM (rituximab-rixa); R-FCM (rituximab-arrx); R-FCM (rituximab-pvvr);

CISMeF acronym : R-FCM;

NCIt definition : A regimen consisting of rituximab, fludarabine, cyclophosphamide and mitoxantrone used to treat indolent non-Hodgkin lymphoma and relapsed or refractory mantle cell lymphoma.;

NCIt note : Source: NCCN Guidelines 2007 and PDQ;

Codes from synonyms : 12266; 128521; 128678; 128207; 127736; 128364; 127893; 128050;

Détails

Origin ID

C63463;

UMLS CUI

C1871911;

Currated CISMeF NLP mapping
- R-FCM protocol [MeSH Supplementary Concept]
- R-FCM protocol [MeSH concept]
Semantic type(s)
- Therapeutic or Preventive Procedure [UMLS semantic type]
UMLS correspondences (same concept)
- R-FCM protocol [MeSH Supplementary Concept]
- R-FCM protocol [MeSH concept]
chemotherapy_regimen_has_component
- Cyclophosphamide [NCIt concept]
- Fludarabine [NCIt concept]
- Mitoxantrone Hydrochloride [NCIt concept]
- Rituximab [NCIt concept]
concept_is_in_subset
- HemOnc Regimen Terminology [NCIt concept]
- Multi-agent Therapeutic Regimens [NCIt concept]
- Pharmacotherapy Regimens [NCIt concept]
regimen_has_accepted_use_for_disease
- Indolent Non-Hodgkin Lymphoma [NCIt concept]
- Recurrent Mantle Cell Lymphoma [NCIt concept]
- Refractory Mantle Cell Lymphoma [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients